Literature DB >> 12370746

Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas.

Ki-Hyuk Shin1, Jin-Man Kim, Kyong Su Rho, Kyung-Hee Park, Ju-Eun Oh, Byung-Moo Min.   

Abstract

PTEN, a tumor suppressor gene, has been found to be inactivated by structural abnormalities or epigenetic changes in several types of human cancers. Recently, several studies have also suggested the possibility that the PTEN gene is a target of genomic instability in human cancers displaying microsatellite instability (MSI). To investigate the role of PTEN in human oral squamous cell carcinomas, we screened the entire coding region sequences and examined the expression of the PTEN gene in 81 oral cancers displaying microsatellite stability (MSS) and 5 oral cancers displaying MSI. Mutation of the PTEN gene was identified in one MSS cancer (1/81; 1.2%) and three MSI cancers (3/5; 60%). The MSS cancer harbored a missense mutation from Ala (GCA) to Val (GTA) at codon 137. Of the MSI cancers containing the PTEN mutation, case 36 had a missense mutation from Lys (AAA) to Glu (GAA) at codon 254, case 43 contained a frameshift mutation (one A deletion) in a 6 bp poly(A) tract affecting codon 265-267, and case 64 harbored two missense mutations from Val (GTG) to Ala (GCG) at codon 222, and from Gly (GGA) to Arg (AGA) at codon 230 indicating biallelic mutation of PTEN. Genomic deletion of exon 5, resulting in loss of PTEN mRNA, was observed in two MSS cancers. In spite of an intact PTEN gene, one MSS and one MSI cancer lacked PTEN mRNA. These findings suggest that the inactivation of PTEN by either mutation or loss of transcript plays a role in the pathogenesis of some oral cancers (8/86; 9.3%). Furthermore, inactivation of PTEN was far more frequent in MSI oral cancers (4/5; 80%) than in MSS oral cancers (4/81; 4.9%).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370746

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

Review 1.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

2.  Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.

Authors:  Ian J Frew; Andrea Minola; Strahil Georgiev; Manuela Hitz; Holger Moch; Stéphane Richard; Alexander O Vortmeyer; Wilhelm Krek
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

Review 3.  Epigenetic disregulation in oral cancer.

Authors:  Massimo Mascolo; Maria Siano; Gennaro Ilardi; Daniela Russo; Francesco Merolla; Gaetano De Rosa; Stefania Staibano
Journal:  Int J Mol Sci       Date:  2012-02-21       Impact factor: 6.208

4.  Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Authors:  Sanjukta Chakraborty; S M Azeem Mohiyuddin; K S Gopinath; Arun Kumar
Journal:  BMC Cancer       Date:  2008-06-06       Impact factor: 4.430

5.  Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.

Authors:  Chien-Hua Peng; Chun-Ta Liao; Ka-Pou Ng; An-Shun Tai; Shih-Chi Peng; Jen-Pao Yeh; Shu-Jen Chen; Kuo-Chien Tsao; Tzu-Chen Yen; Wen-Ping Hsieh
Journal:  Oncotarget       Date:  2015-08-14

Review 6.  Current Insights into Oral Cancer Epigenetics.

Authors:  Alexandra Iulia Irimie; Cristina Ciocan; Diana Gulei; Nikolay Mehterov; Atanas G Atanasov; Diana Dudea; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2018-02-27       Impact factor: 5.923

7.  Prognostic value of the PIK3CA, AKT, and PTEN mutations in oral squamous cell carcinoma: literature review.

Authors:  Anna Starzyńska; Aleksandra Sejda; Paulina Adamska; Giulia Marvaso; Monika Sakowicz-Burkiewicz; Łukasz Adamski; Barbara A Jereczek-Fossa
Journal:  Arch Med Sci       Date:  2020-11-13       Impact factor: 3.318

8.  Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

Authors:  Ann Marie Egloff; Jennifer Rubin Grandis
Journal:  J Oncol       Date:  2009-07-14       Impact factor: 4.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.